EvoWorks Bio

EvoWorks Bio is a private bioprocessing and life science tools company developing an elastically scalable cell culture platform intended to bridge the gap between benchtop development and larger-scale biologics production. Its core EvoNode platform is positioned for preclinical biologics teams, diagnostic antibody developers, CROs, and CDMOs that need more predictable scale-up for transient CHO expression, rapid tox workflows, and recurring antibody production. Rather than advancing a proprietary therapeutic pipeline, the company appears to sell platform-enabled services and in-lab systems that aim to reduce process transfer risk, lower capital requirements, and shorten timelines to usable material. The company is based in Cambridge, Massachusetts, was founded in 2023, and has been associated with The Engine, BioTools Innovator, and BARDA-backed VANGUARD programming. Overall, EvoWorks Bio is best understood as a biotech infrastructure/platform company focused on scalable biomanufacturing rather than a drug developer.